Greenwood Capital Associates LLC Has $5.15 Million Position in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Greenwood Capital Associates LLC trimmed its stake in Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 1.4% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 233,525 shares of the company’s stock after selling 3,240 shares during the quarter. Greenwood Capital Associates LLC’s holdings in Teva Pharmaceutical Industries were worth $5,147,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently bought and sold shares of TEVA. Stifel Financial Corp lifted its stake in shares of Teva Pharmaceutical Industries by 54.0% in the third quarter. Stifel Financial Corp now owns 66,391 shares of the company’s stock valued at $1,196,000 after buying an additional 23,283 shares in the last quarter. Thrivent Financial for Lutherans raised its stake in shares of Teva Pharmaceutical Industries by 21.8% during the 3rd quarter. Thrivent Financial for Lutherans now owns 224,511 shares of the company’s stock worth $4,046,000 after purchasing an additional 40,218 shares during the period. Sio Capital Management LLC purchased a new position in shares of Teva Pharmaceutical Industries in the 3rd quarter worth about $24,314,000. CWA Asset Management Group LLC bought a new position in Teva Pharmaceutical Industries during the fourth quarter valued at about $3,340,000. Finally, Two Sigma Advisers LP increased its holdings in Teva Pharmaceutical Industries by 15.3% during the third quarter. Two Sigma Advisers LP now owns 1,034,500 shares of the company’s stock worth $18,642,000 after buying an additional 137,000 shares during the last quarter. 54.05% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of analysts have issued reports on the company. JPMorgan Chase & Co. raised their target price on Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the stock a “neutral” rating in a research report on Monday, October 21st. StockNews.com lowered shares of Teva Pharmaceutical Industries from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, December 18th. UBS Group lowered their price target on shares of Teva Pharmaceutical Industries from $30.00 to $27.00 and set a “buy” rating on the stock in a research report on Thursday, January 30th. Piper Sandler increased their target price on Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the stock an “overweight” rating in a research report on Friday, January 17th. Finally, Barclays reduced their price target on Teva Pharmaceutical Industries from $28.00 to $26.00 and set an “overweight” rating for the company in a research report on Thursday, January 30th. Two analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $22.00.

Teva Pharmaceutical Industries Trading Down 0.1 %

Shares of TEVA opened at $17.34 on Tuesday. Teva Pharmaceutical Industries Limited has a 1-year low of $11.83 and a 1-year high of $22.80. The company has a market capitalization of $19.64 billion, a P/E ratio of -11.99, a P/E/G ratio of 1.43 and a beta of 0.71. The company has a debt-to-equity ratio of 2.57, a current ratio of 0.89 and a quick ratio of 0.61. The firm’s 50 day simple moving average is $20.00 and its 200 day simple moving average is $18.50.

Teva Pharmaceutical Industries (NYSE:TEVA) last posted its quarterly earnings data on Wednesday, January 29th. The company reported $0.70 earnings per share for the quarter, beating the consensus estimate of $0.69 by $0.01. Teva Pharmaceutical Industries had a negative net margin of 9.91% and a positive return on equity of 40.20%. Sell-side analysts forecast that Teva Pharmaceutical Industries Limited will post 2.62 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, Director Roberto Mignone sold 286,000 shares of the business’s stock in a transaction dated Friday, December 20th. The stock was sold at an average price of $22.01, for a total value of $6,294,860.00. Following the completion of the sale, the director now owns 695,000 shares of the company’s stock, valued at approximately $15,296,950. The trade was a 29.15 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Christine Fox sold 19,388 shares of the firm’s stock in a transaction that occurred on Wednesday, November 20th. The stock was sold at an average price of $16.87, for a total transaction of $327,075.56. Following the completion of the transaction, the executive vice president now owns 44,104 shares in the company, valued at $744,034.48. This represents a 30.54 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 0.55% of the company’s stock.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.